Nektar Therapeutics (NASDAQ: NKTR) is 107.08% higher on its value in year-to-date trading and has touched a low of $0.42 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NKTR stock was last observed hovering at around $1.28 in the last trading session, with the day’s loss setting it -0.11%.
Currently trading at $1.17, the stock is -12.16% and -9.67% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.36 million and changing -8.59% at the moment leaves the stock -4.46% off its SMA200. NKTR registered 129.41% gain for a year compared to 6-month loss of -35.00%. The firm has a 50-day simple moving average (SMA 50) of $1.2952 and a 200-day simple moving average (SMA200) of $1.22475.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -15.22% gain in the last 1 month and extending the period to 3 months gives it a -6.40%, and is -14.60% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.93% over the week and 6.94% over the month.
Nektar Therapeutics (NKTR) has around 137 employees, a market worth around $215.82M and $93.14M in sales. Profit margin for the company is -180.70%. Distance from 52-week low is 176.79% and -39.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.09%).
The EPS is expected to grow by 49.00% this year
174.0 institutions hold shares in Nektar Therapeutics (NKTR), with institutional investors hold 76.45% of the company’s shares. The shares outstanding are 191.38M, and float is at 177.81M with Short Float at 2.94%. Institutions hold 75.65% of the Float.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 17.88 million shares valued at $22.17 million. The investor’s holdings represent 9.1789 of the NKTR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 15.16 million shares valued at $18.79 million to account for 7.7823 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 12.97 million shares representing 6.6587 and valued at over $16.08 million, while SAMLYN CAPITAL, LLC holds 4.8565 of the shares totaling 9.46 million with a market value of $11.73 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Zalevsky Jonathan, the company’s Chief R&D Officer. SEC filings show that Zalevsky Jonathan sold 6,866 shares of the company’s common stock on Aug 19 ’24 at a price of $1.28 per share for a total of $8788.0. Following the sale, the insider now owns 0.25 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Aug 19 ’24 that Wilson Mark Andrew (Chief Legal Officer) sold a total of 5,651 shares of the company’s common stock. The trade occurred on Aug 19 ’24 and was made at $1.28 per share for $7233.0. Following the transaction, the insider now directly holds 0.23 million shares of the NKTR stock.
Still, SEC filings show that on Aug 19 ’24, ROBIN HOWARD W (President & CEO) disposed off 14,881 shares at an average price of $1.28 for $19048.0. The insider now directly holds 848,358 shares of Nektar Therapeutics (NKTR).
